Mitokinin
Dr. Dawson is the Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases and Director of the Institute for Cell Engineering at the Johns Hopkins University School of Medicine. He brings his deep expertise in the PINK1/Parkin pathway and Parkinson’s disease pathobiology to the Mitokinin team as a member of the Scientific Advisory Board.
Dr. Dawson pioneered the role of nitric oxide in neuronal injury in stroke and excitotoxicity and elucidated the molecular mechanisms by which nitric oxide and poly (ADP-ribose) polymerase kills neurons. Dr. Dawson’s discoveries have led to innovative approaches and enhanced the development of new agents to treat neurologic disorders, such as Parkinson’s disease and Alzheimer’s disease as well as other neurodegenerative disorders.
This person is not in the org chart
This person is not in any offices
Mitokinin
Mitokinin is operates in the healthcare industry focusing on biotechnology business. Mitokinin has advanced small molecule therapeutics that specifically increase the activity of active-form PINK1. Importantly, Mitokinin’s compounds do not interfere with the endogenous regulation of PINK1. PINK1 is a master regulator of mitochondrial quality control. Mutations in PINK1 give rise to familial forms of Parkinson’s disease. Increased PINK1 activity rescues pathologies associated with neurodegenerative disease. Mitokinin has an accomplished team of neuroscientists, chemists, pharmacologists, and administrative professionals all focused on our mission: delivering disease-modifying therapies for neurodegenerative disease.